GlassScriptPhysician profile
Lena Bruce
NPI 1558322438
$7,964.40
in general payments reported to CMS, 2019-2025
46 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $1,458 · 2021: $754 · 2022: $1,189 · 2023: $683 · 2024: $1,468 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,235.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,135.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $833.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $655.03 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $649.73 | 2022-2025 | |
| Abbvie INC. | $272.99 | 2020-2025 | Creon, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.71 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $203.65 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Pfizer INC. | $198.72 | 2019-2025 | |
| Eisai INC. | $179.19 | 2020-2021 | |
| Corium, LLC | $168.30 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $167.31 | 2019-2023 | Tlando, Xyosted |
| Antares Pharma, INC. | $148.85 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $134.21 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.